Review this patient's summary. Do they not have molecular markers

Molecular Markers Status for Alan Stucchi

Based on the clinical summary, molecular markers testing has not yet been completed for Alan's glioblastoma. Here's what the document shows:

Current Status:

According to the document's "Molecular/Genomic Findings & Biomarkers" section:

• NGS testing not yet completed — NGS (Next-Generation Sequencing) is a comprehensive genetic test that identifies mutations in tumor cells
• Standard glioblastoma molecular markers status unknown from the available [ID removed]
• Protean BioPharma package being considered — this suggests the care team is actively planning to do this testing

Why This Matters:

For glioblastoma patients, molecular markers are important because they can identify:

• Specific mutations that might respond to targeted therapies (drugs designed to attack particular genetic changes)
• Prognostic information (how the disease might behave)
• Treatment options that might not be available without knowing the tumor's genetic profile

Key Recommendation:

The clinical summary specifically recommends: "Prioritize NGS testing to identify potential targetable mutations" — suggesting this is considered an important next step in Alan's care.

This testing could potentially open doors to clinical trials or targeted treatment options that aren't currently being pursued. Given Alan's aggressive, treatment-resistant disease pattern, comprehensive genomic profiling appears to be a priority for his medical team.